Latest Headlines

Latest Headlines

Canadian researchers developing genomics tools to combat swine diseases

A team of Canadian researchers has been formed to develop new genomics tools they hope will lead to the breeding of pigs resistant to multiple swine diseases.

IBM inks deals to give Watson a role in R&D at Icon and Teva

The march of IBM's Watson into biopharma R&D is continuing apace. Icon and Teva are the latest companies to ink deals to access the computer system, giving them new ways to match patients to clinical trials and create disease models.

Big-name academic centers round up $20M to dig into ALS data

Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital have raised $20 million to fuel a research initiative to understand the cause of amyotrophic lateral sclerosis.

UPDATED: Melinta's CEO steps down amid a big Phase III push

Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech raised $67 million in equity financing.

Lilly upsizes its new Cambridge, MA, R&D shop as Big Pharma crowds the neighborhood

Eli Lilly, blueprinting an R&D hub outside Boston, is expanding the square footage of its new outpost, snatching up more of the increasingly costly lab space in biotech's most in-demand neighborhood.

Exosome Diagnostics reveals positive data for lung cancer liquid biopsy test

Exosome Diagnostics is trotting out promising data for its lung cancer liquid biopsy test, a week after reeling in new funds to support development of its liquid biopsy technology and build out its portfolio.

ShiftLab's first device is nearing commercialization. Will it start a low-cost revolution?

Engineering professor Beth Kolko is on a mission to sell low-cost devices. She's dismayed at the current landscape, which favors high-cost devices because cheaper alternatives can't support the sales forces needed to sell them, according to one industry exec.

Next-gen antibody experts at AnaptysBio file $86M IPO

Up to now, San Diego-based AnaptysBio has raised close to $49 million in cash directly from collaborators looking to the antibody shop to use their technology to create some promising new programs--slightly more than its cumulative burn rate over the years. Now, it's filed papers with the SEC for an $86 million IPO, looking to join the queue of biotechs out to test the marketplace in the wake of some severe turbulence.

CureVac turns to Cambridge, MA, to jump-start its mRNA pipeline

Germany's CureVac has launched a subsidiary in the biotech hotbed of Cambridge, MA, hoping to accelerate the development of its messenger RNA therapies on the heels of a major investment from the Bill and Melinda Gates Foundation.

Philips opens its first digital health innovation center in the Netherlands, with more to come

Royal Philips has started its first center to back digital healthcare innovation at High Tech Campus Eindhoven in the Netherlands. The "co-creation center" is intended to be the first of several global R&D sites in which the conglomerate supports the development of healthcare solutions focused on patient self-management and continuity of care.